CG Oncology's Promising Outlook in Cancer Therapy Development

Price Target and Market Performance: Morgan Stanley set a price target of $93 for NASDAQ:CGON, indicating a potential increase of about 71.59% from its current trading price.Strong Buy Rating: CG Oncology received a "Strong Buy" rating due to its pipeline progress and upcoming catalysts, particularly for its bladder cancer treatments.Key Developments and FDA Approval Potential: The company's early completion of enrollment in the phase 3 PIVOT-006 trial and the rolling BLA for cretostimogene highlight signif ...